Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

NCT00073736 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: MB07133 300mg/m2/day
DRUG: MB07133 600 mg/m2/day
DRUG: MB07133 1200 mg/m2/day
DRUG: MB07133 1800 mg/m2/day
DRUG: MB07133 2400 mg/m2/day

Sponsor

Ligand Pharmaceuticals